Close



Dec 8, 2022 08:00AM
Nov 3, 2022 07:30AM
Aug 9, 2022 07:30AM
Jun 13, 2022 08:00AM
May 10, 2022 07:30AM
Apr 25, 2022 07:03AM
Apr 25, 2022 07:00AM Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
Mar 1, 2022 07:30AM
Dec 20, 2021 11:39AM
Dec 20, 2021 10:17AM
Dec 20, 2021 08:58AM
Dec 20, 2021 08:28AM
Dec 20, 2021 06:47AM
Dec 20, 2021 06:47AM Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
Dec 6, 2021 06:41AM
Nov 9, 2021 07:30AM
Oct 21, 2021 08:42AM
Oct 18, 2021 05:18AM
Sep 27, 2021 07:30AM
Sep 27, 2021 07:30AM
Sep 20, 2021 07:30AM Intra-Cellular Therapies Announces Publications Highlighting Beneficial Effects of Phosphodiesterase Type I Inhibition with Lenrispodun (ITI-214) on Cardiovascular Function in Patients with Heart Fail
Aug 9, 2021 07:30AM
Jun 7, 2021 08:05AM
Jun 7, 2021 08:00AM
May 10, 2021 07:35AM
May 10, 2021 07:30AM
May 3, 2021 07:31AM
May 3, 2021 07:30AM Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
Apr 22, 2021 07:30AM
Apr 20, 2021 07:00AM
Apr 19, 2021 09:05AM
Apr 12, 2021 07:30AM
Feb 25, 2021 07:30AM
Feb 24, 2021 07:30AM
Feb 22, 2021 08:09AM Intra-Cellular Therapies (ITCI) Applies for FDA Approval of CAPLYTA for the Treatment of Bipolar Depression
Feb 22, 2021 08:00AM
Jan 21, 2021 08:09AM
Jan 21, 2021 08:00AM
Dec 29, 2020 08:01AM
Dec 29, 2020 08:00AM
Dec 9, 2020 08:00AM
Nov 9, 2020 07:30AM Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Sep 9, 2020 07:01AM
Sep 9, 2020 07:00AM
Aug 10, 2020 07:30AM
Jun 29, 2020 08:01AM
Jun 29, 2020 08:00AM
May 7, 2020 07:30AM
Apr 2, 2020 08:00AM Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults
Mar 23, 2020 07:30AM

212,766 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All